Identifying breast cancer patients most likely to benefit from aromatase inhibitor therapy after adjuvant radiation and tamoxifen

Cancer

Volumn 107, Issue 11, 2006, Pages 2552-2558

  Freedman, Gary M ^a   Anderson, Penny ^a   Li, Tianyu ^a   Ross, Eric ^a   Swaby, Ramona ^a   Goldstein, Lori ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

Breast cancer; Event free survival; Hormonal therapy; Radiation therapy

Indexed keywords

AROMATASE INHIBITOR; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; METHOTREXATE; PACLITAXEL; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RECURRENCE; COMORBIDITY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; OVERALL SURVIVAL; PATIENT IDENTIFICATION; PATIENT SELECTION; PREMENOPAUSE; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; AROMATASE INHIBITORS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; RADIOTHERAPY, ADJUVANT; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SURVIVAL RATE; TAMOXIFEN; TREATMENT OUTCOME;

EID: 33751581586     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22291     Document Type: Article

References (9)

1. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687-1717.
2. Fisher B, Dignam J, Bryant J, Wolmark N. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst. 2001;93:684-690.
3. Goss PE, Ingle JN, Martino S, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst. 2005;97:1262-1271.
4. Greene FL, Page DL, Fleming ID, et al., editors. AJCC Cancer Staging Manual. 6th ed. New York: Springer-Verlag; 2002.
5. Fowble B, Freedman G. Cancer of the breast. In: Wang CC, editor. Clinical Radiation Oncology: Indications, Techniques and Results. 2nd ed. New York: Wiley-Liss; 2000.
6. National Comprehensive Cancer Network. NCCN practice guidelines for breast cancer. 2005. Available at URL: http://www.nccn.org/professionals/ physician_gls/PDF/breast.pdf [accessed August 31, 2006].
7. Saphner T, Tormey DC, Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol. 1996;14:2738-2746.
8. Boccardo F, Rubagotti A, Amoroso D, et al. Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-/perimenopausal breast cancer patients: results of the Italian Breast Cancer Adjuvant Study Group 02 randomized trial. J Clin Oncol. 2000;18:2718-2727.
9. United States Department of Health and Human Services. Bone Health and Osteoporosis. A Report of the Surgeon General. Washington, DC: Government Printing Office; 2004.